Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
– Plozasiran reduced triglycerides by 80% from baseline and reduced the risk of developing acute…
O2 and Mavenir successfully trial technology to improve call clarity for people with hearing loss